Status:
COMPLETED
Genetic Factors on Outcomes of Kidney Transplant Patients With Tacrolimus-based Therapy
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Kidney Transplantation
Eligibility:
All Genders
20-65 years
Brief Summary
The purpose of this study is to identify the influence of genetic and clinical factors on the clinical outcomes of kidney transplant patients with tacrolimus (TAC) based immunosuppression in Taiwan.
Detailed Description
Tacrolimus (TAC) is the most important immunosuppressants for maintenance therapy after kidney transplantation. Many genetic and clinical factors had been found to have effect on TAC pharmacokinetics ...
Eligibility Criteria
Inclusion
- Kidney transplantation
- 20-65 years old
- Receiving tacrolimus-based immunosuppressants
- Were recruited in a previous trial
Exclusion
- Human immunodeficiency virus-positive status
- Retransplantation or multiorgan transplantation
- Non-Asian
Key Trial Info
Start Date :
November 30 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 22 2020
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT03764670
Start Date
November 30 2018
End Date
September 22 2020
Last Update
March 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan